← Back
Clinical Medicine and Surgery I · Exam 8 · Class of 2028

CMS I Exam 8 Cram Sheet

Criteria, scores and classifications first: one table per set from the slides, each with a labeled memory aid. Hematology Block Exam, condensed from the Exam 8 study guide. Lectures covered: 46 (cytopenias and hemochromatosis), 49 (hematologic malignancies part I), 50 (hematologic malignancies part II). Each lecture opens with a gold card of what its lecturer stressed (starred; from the lecture recording); every fact still comes from the slides.

How to use this: this is a condensed, night-before-the-exam reference, not a replacement for the full study guide — it assumes you've already learned the material and just need the highest-yield facts at a glance. If a term feels unfamiliar, go back to the full guide for the explanation.

Red Blood Cell Indices: Normal RangesReference values · Lecture 46 · slide 7

IndexWhat it measuresNormal
Mean corpuscular volume (MCV)Average size of red blood cells80–100 fL (femtoliters)
Mean corpuscular hemoglobin (MCH)Amount of hemoglobin in each red blood cell27–31 pg/cell (picograms)
Mean corpuscular hemoglobin concentration (MCHC)Hemoglobin relative to the size of each red blood cell32–36 g/dL (320–360 g/L)
Red cell distribution width (RDW)Differences in the volume and size of the red cells; healthy cells are about the same sizeNo number on the slide
Hemoglobin and hematocrit (H&H)Hemoglobin: the amount in the blood. Hematocrit: the percentage of red cells in total blood volumeNo number on the slide
Initial approach (slide 8): history and physical, then the complete blood count: all three cell lines (red cells, white cells, platelets), look for pancytopenia, read the MCV, and use the reticulocyte index to judge whether the marrow response is adequate.
Memory aid

Size up to 100; weight a month’s worth; concentration just past the month.

100 MCV 80–100 fL (size)A month MCH 27–31 pg/cell, like the days in a month (weight per cell)Past the month MCHC 32–36 g/dL (concentration)

Where it breaks: Red cell distribution width and the H&H have no number on the slide.

Anemia of Chronic Disease vs Iron DeficiencyComparison · Lecture 46 · slides 27, 13, 25 ★

Anemia of chronic diseaseIron deficiency anemia
Red cells, hemoglobin, hematocrit↓ (mild)↓
Mean corpuscular volumeNormal or ↓↓
Mean corpuscular hemoglobin and its concentrationNormal or ↓↓
Red cell distribution widthVaries↑
ReticulocytesUsually ↓Varies
Serum iron↑ or ↓ (slide 27)↓
FerritinNormal or ↑↓
Total iron-binding capacity (TIBC)↓↑
Coexisting iron deficiency (slide 25)Ferritin <30 ng/mL (67 pmol/L)—
Slide conflict: slide 13 gives anemia of chronic disease a low serum iron and transferrin saturation with a normal or low TIBC; slide 27 gives its serum iron as “↑ or ↓”. TIBC also differs: normal or low on slide 13, ↓ on slide 27 (never above normal on either). Both agree on ferritin (normal or ↑): tell them apart by ferritin with TIBC, never by serum iron alone. Ferritin is an acute phase reactant, so a normal or high ferritin does not exclude iron deficiency (slide 14); order an ESR (erythrocyte sedimentation rate) and/or CRP (C-reactive protein) if inflammation is a concern.
Memory aid

Iron deficiency: the Tank (ferritin) is empty, so more Trucks (TIBC) go out looking. Chronic disease: hepcidin Locks the tank: the Tank is full or normal, and fewer Trucks are sent.

Tank empty iron deficiency: ferritin ↓More trucks iron deficiency: TIBC ↑Tank locked chronic disease: ferritin normal or ↑Fewer trucks chronic disease: TIBC ↓

Where it breaks: The tank says nothing about serum iron in chronic disease (↑ or ↓ on slide 27, low on slide 13), or about the indices and red cell distribution width; “fewer trucks” is slide 27 (slide 13: normal or low TIBC).

Macrocytic Anemia: Cut-offs and CategoriesCut-off · Lecture 46 · slides 38–39

MegaloblasticNon-megaloblastic
Defined asMacrocytic anemia with megaloblasts (early red cell precursors): macro-ovalocytes, hypersegmented neutrophilsMacrocytic anemia without megaloblasts
CausesVitamin B12 and folate deficiencyAlcohol (common) or drug; hypothyroidism; liver failure; bone marrow dysplasia
Mean corpuscular volume>100 fL (all macrocytic anemia)>100 fL, but usually <115 fL
MechanismImpaired DNA synthesis → nuclear-cytoplasmic asynchrony; granulocytes and megakaryocytes affected to a lesser degree—
Memory aid

Macrocytic starts at 100; non-megaloblastic usually stops at 115. The non-megaloblastic causes: Alcohol Hits Liver and Marrow.

100 MCV >100 fL defines macrocytic anemia115 non-megaloblastic causes usually stay below 115 fLAlcohol alcohol (common) or drugHits hypothyroidismLiver liver failureMarrow bone marrow dysplasia

Where it breaks: The megaloblastic column (B12 and folate, megaloblasts, hypersegmented neutrophils, impaired DNA synthesis) is not in the hook.

Complete Blood Count: Megaloblastic AnemiaLab pattern · Lecture 46 · slide 41

ParameterMegaloblastic anemia (macrocytic, normochromic)
Red cells, hemoglobin, hematocrit↓
Mean corpuscular volume↑ (macrocytosis)
Mean corpuscular hemoglobin and its concentrationNormal to slightly ↑
Red cell distribution width↑ (anisocytosis)
ReticulocytesVaries
Memory aid

Big and Uneven: the cells are bigger (MCV up) and of uneven sizes (RDW up); the counts fall and the color stays normal.

Big MCV ↑ (macrocytosis)Uneven RDW ↑ (anisocytosis)Counts fall red cells, hemoglobin, hematocrit ↓Normal color MCH, MCHC normal to slightly ↑ (normochromic)

Where it breaks: Reticulocytes (varies) are not in the hook.

Complete Blood Count: Anemia of Chronic Kidney DiseaseLab pattern · Lecture 46 · slides 52–53

ParameterAnemia of chronic kidney disease
Red cells, hemoglobin, hematocrit↓
Mean corpuscular volumeNormal
Mean corpuscular hemoglobin and its concentrationNormal
Red cell distribution width↑
Reticulocytes↓
Primarily, but not completely, from decreased erythropoietin; incidence rises as the glomerular filtration rate falls, almost universal on dialysis (slide 52). Slide 53: a low transferrin saturation may mean iron-restricted erythropoiesis despite a normal or high ferritin.
Memory aid

Normal-sized cells with no factory order: the kidney stops sending erythropoietin, so the cells look normal but too few are made.

Normal-sized MCV, MCH, MCHC normalNo factory order reticulocytes ↓ (low erythropoietin)Too few red cells, hemoglobin, hematocrit ↓

Where it breaks: The red cell distribution width is ↑ even though the indices are normal.

Vitamin B12 vs Folate: the LabsCriteria · Lecture 46 · slides 47–48, 50 ★

TestWhat the slide saysSeparates B12 from folate?
B12 and folate levelsThe initial tests for all macrocytic anemias, with a peripheral smear; not very sensitive—
HomocysteineMetabolism of homocysteine to methionine requires both B12 and folateNo (needs both)
Methylmalonic acid (MMA)Metabolism of L-methylmalonyl CoA to succinyl CoA requires only B12: MMA is elevated in B12 deficiency but NOT folate deficiencyYes
IF PERNICIOUS ANEMIA IS SUSPECTED (slides 48, 50)
Anti-intrinsic factor antibodiesSometimes detected; specific but not sensitive
Anti-parietal cell antibodiesMay be present; not sensitive or specific
Gastric biopsyMay show chronic atrophic gastritis
Parenteral B12 trialIn reality, a megaloblastic picture that corrects with B12 is the normal diagnostic pathway
Homocysteine and MMA are ordered when the B12 and folate levels are borderline or suspicion continues. Before replacing folate, evaluate for B12 deficiency: the labs may improve while permanent neurologic symptoms worsen (slide 49).
Memory aid

Homocysteine is a shared Home (both vitamins live there); MMA is B12’s alone: “Methylmalonic Means B12 Alone”.

Home homocysteine needs B12 and folate, so it cannot tell them apartAlone MMA needs only B12: up in B12, not folate, deficiencySpecific, not sensitive anti-intrinsic factor antibodiesNeither anti-parietal cell antibodies

Where it breaks: The first-line B12 and folate levels, the gastric biopsy and the B12 trial are not in the hook.

Absolute Neutrophil Count & Febrile NeutropeniaFormula and cut-offs · Lecture 46 · slides 59–60

ItemSlide wording
Leukopenia vs neutropeniaLeukopenia = a low total white count; neutropenia is defined by the absolute neutrophil count (ANC)
FormulaANC = white count × (neutrophils + bands)% / 100
MildANC 1,000–1,500 cells/µL
ModerateANC 500–999
SevereANC <500
FEBRILE NEUTROPENIA (slide 60)
EmergencyFever with ANC <500 (or expected to fall below 500): prompt assessment and empiric antibiotics
ImmediatelyVitals, targeted examination and cultures; start antipseudomonal therapy without delay
RiskSeverity, duration and immune status predict infection risk; profound neutropenia may have subtle findings
Escalate to hematology (slide 59)Persistent or unexplained severe neutropenia, other cytopenias, or an abnormal smear
Memory aid

Count the Neutrophils AND the Bands, then step down by 500: 1500, 1000, 500. Fever under 500 is a fire alarm: cultures and antipseudomonal antibiotics now.

Neutrophils + bands the percentage that multiplies the white count, / 100Below 1500 mild 1,000–1,500Below 1000 moderate 500–999500 severe <500Fire alarm fever + ANC <500 (or expected): empiric antipseudomonal antibiotics without delay

Hemolysis: the LabsCriteria · Lecture 46 · slides 61, 66–70 ★

TestIn hemolysis
Bilirubin (conjugated and unconjugated)Both likely elevated, unconjugated > conjugated
JaundiceAppears when total bilirubin exceeds 2.0 mg/dL (normal 0.3–1.2 mg/dL)
HaptoglobinDECREASED or absent with intravascular hemolysis (it picks up free hemoglobin)
Lactate dehydrogenase (LDH)A cytoplasmic enzyme, elevated with any cellular lysis
Peripheral smearThe hallmark finding: schistocytes (red blood cell fragments)
Reticulocyte countOften the first indication; an unexpected rise, even without anemia or symptoms, should prompt consideration of hemolysis
UrinalysisSome hemoglobin reaches the urine in intravascular hemolysis
Workup for a suspected hemolytic anemia (slide 69): complete blood count, reticulocyte count, serum bilirubin, LDH, haptoglobin, urinalysis, peripheral smear review. Extravascular hemolysis (spleen and liver macrophages) is the more common route (slide 66).
Memory aid

Broken cells Spill: Bilirubin and LDH go Up, Haptoglobin gets Used up, the Smear shows Shards, and the marrow sends more Retics.

Up bilirubin (unconjugated > conjugated) and LDH elevated2.0 jaundice above total bilirubin 2.0 mg/dLUsed up haptoglobin decreased or absent (intravascular)Shards schistocytes, the hallmarkRetics reticulocytes up, often the first sign

Causes of Hemolysis: Intra- vs ExtracorpuscularClassification · Lecture 46 · slides 64–65

CategoryExamples
INTRACORPUSCULAR (intrinsic to the red cell)
HemoglobinopathiesSickle cell disease, thalassemia, unstable hemoglobin variants
Membrane / cytoskeletal defectsHereditary spherocytosis, elliptocytosis, stomatocytosis
Metabolic abnormalitiesG6PD (glucose-6-phosphate dehydrogenase) and pyruvate kinase deficiencies
EXTRACORPUSCULAR
Immune-mediatedAutoimmune hemolytic anemia, transfusion reactions
Hypersplenism
Mechanical traumaShear stress
Oxidative stressG6PD, methemoglobinemia
InfectionMalaria, babesiosis
ToxinSnake and insect bites, burns, copper poisoning
Memory aid

Inside the cell it says “HMM”; from outside a MOTH II attacks it.

H Hemoglobinopathies (inside)M Membrane/cytoskeleton (inside)M Metabolic: G6PD, pyruvate kinase (inside)M Mechanical trauma (outside)O Oxidative stress (outside)T Toxin (outside)H Hypersplenism (outside)I Immune-mediated (outside)I Infection (outside)

Where it breaks: G6PD sits on both sides: a metabolic defect inside the cell (slide 64) and oxidative stress outside it (slide 65).

Autoimmune Hemolytic Anemia: Stabilize and TreatCriteria · Lecture 46 · slides 71–74

ItemSlide wording
Consider immediate stabilization ifHemoglobin <6, a rapid decline, or the patient is unstable; contact the blood bank (will need to find compatible blood)
TestDirect antiglobulin (Coombs) test: positive when the washed red cells carry IgG or complement
TreatRule out secondary causes; glucocorticoids first (e.g., prednisone 60–100 mg daily); rituximab (anti-CD20); others: immunosuppressants, splenectomy
Important noteIncreased risk of venous thromboembolism: consider D-dimer and bilateral leg ultrasound; venous thromboembolism prophylaxis for inpatients, consider in outpatients
Secondary causesViruses (human immunodeficiency virus (HIV), hepatitis, Epstein-Barr virus (EBV), SARS-CoV-2); autoimmune (lupus, rheumatoid arthritis, scleroderma, ulcerative colitis); lymphoproliferative (leukemia, lymphoma, multiple myeloma); pregnancy. Primary is almost always IgG
Memory aid

Six, Sliding, Shaky: stabilize now. Then Steroids first, then the anti-CD20, and watch for Clots.

Six hemoglobin <6Sliding rapid declineShaky unstable patientSteroids glucocorticoids initiallyAnti-CD20 rituximabClots increased venous thromboembolism risk

Where it breaks: The Coombs test and the secondary causes are not in the hook.

G6PD Deficiency: Triggers and TimingCriteria · Lecture 46 · slides 79, 81–82 ★

#Common trigger (slide 79)
1Fava beans
2Naphthalene (mothballs)
3Antimalarials (the slide names chloroquine; out loud, chloroquine does not carry the same risk)
4Nitrofurantoin
5Trimethoprim-sulfamethoxazole (Bactrim)
6Methylene blue
7Phenazopyridine
8Quinolones
TIMING (slides 81–82)
LagDrug-induced hemolysis is acute, of variable severity, with a lag of 2–3 days; no symptoms until exposed to oxidative stress
SmearDuring an attack: Heinz bodies and bite cells
ConfirmA low G6PD level roughly 8 weeks after an attack (the slide asks “Why not during an attack?”)
Slide conflict: slide 79 lists “antimalarials (chloroquine, etc)” while the slide 83 table lists chloroquine as safe for class II and III variants. Prof. Ward sided with the table out loud: “don’t just assume all anti-malarial medications carry that same risk.” Some antimalarials trigger hemolysis, not every one; no antimalarial is keyed.
Memory aid

Fried Nachos And Nuts Turn My Pee Questionable (dark urine is the symptom).

Fried Fava beansNachos Naphthalene (mothballs)And Antimalarials (some; not chloroquine, per Prof. Ward)Nuts NitrofurantoinTurn Trimethoprim-sulfamethoxazoleMy Methylene bluePee PhenazopyridineQuestionable Quinolones

Thalassemia: Alpha Genotypes and LabsClassification · Lecture 46 · slides 86–89

ItemSlide wording
Genes4 alpha globin genes and 2 beta globin genes; the phenotype depends on how many are mutated
Silent carrierα−/αα: the mild end of the range
Alpha thalassemia 1 traitαα/−−: often in Asian ancestry; higher risk of hydrops fetalis
Alpha thalassemia 2 traitα−/α−: more often in African ancestry (mild forms)
Far endIncompatible with life
Where alpha is prevalentSouthern China, Malaysia, Thailand, the Mediterranean region
LABS (slides 87–88)
PatternGenerally ↓ hemoglobin, ↓ MCV, ↓ MCH, ↓ reticulocyte index (marrow failure), Coombs negative; iron overload (bold, underlined)
OrderComplete blood count, iron studies, reticulocyte count; hemoglobin electrophoresis; gene testing
Slide 13: thalassemia gives more microcytosis for its hemoglobin level, with a normal or elevated red cell count. Slide conflict: slide 13 also says thalassemia has a reticulocytosis, while slide 87 gives a ↓ reticulocyte index (marrow failure); the reticulocyte direction is not keyed. Slide 86 places beta thalassemia “generally in patients of African origin”; that ancestry claim is not keyed.
Memory aid

Trait 1: both dashes on 1 side of the slash (Asian, hydrops risk). Trait 2: the dashes split over 2 sides (African, mild).

1 side αα/−− = alpha thalassemia 1 trait, Asian ancestry, higher hydrops fetalis risk2 sides α−/α− = alpha thalassemia 2 trait, African ancestry1 dash α−/αα = silent carrier

Where it breaks: The slash rule is about the slide’s notation only; the lab pattern is not in the hook.

Hemoglobin S, C, SC and FClassification · Lecture 46 · slides 90–91, 96–97

HemoglobinMake-upBehavior
S (sickle)Two alpha + two mutant beta globins (α2βS2)Polymerizes under low oxygen tension → sickle shape
CA different beta globin mutationDoes not polymerize
SC (sickle cell SC)βC with βS (α2βSβC)Course generally between sickle cell anemia and sickle cell trait
F (fetal)α2γ2Normally <1%; 10–20% seems a threshold for decreased severity of sickle cell disease or beta thalassemia (hereditary persistence of fetal hemoglobin)
Sickle trait (HbAS) carriers are 90% less likely to have severe malaria; the disease follows the malaria belt (slide 91).
Memory aid

S Sickles, C Can’t, SC sits in the Center, F Fends it off at 10–20%.

Sickles HbS polymerizes at low oxygen tensionCan’t HbC does not polymerizeCenter HbSC: between anemia and traitFends HbF normally <1%; 10–20% lessens sickle cell and beta thalassemia severity

Sickle Cell Disease: the Four Screening PeriodsClassification · Lecture 46 · slide 92

PeriodSlide wording
PreconceptionIdentify parents whose offspring would be at risk
PrenatalCan be done by chorionic villus sampling
NeonatalNow done in all 50 states. Those who test negative or bypass screening usually present within the first two years; symptoms start around 5 months (HbF to HbS transition): failure to thrive, pain, anemia, splenomegaly, chronic infections, swelling of the extremities (vaso-occlusion)
Post-natalNo detail on the slide
The slide gives a gestational week for chorionic villus sampling; it is not keyed (the periods are).
Memory aid

Before you Pair, before you’re Born, as a Baby, and After.

Pair preconceptionBorn prenatal (chorionic villus sampling)Baby neonatal: all 50 states; symptoms around 5 monthsAfter post-natal

Hemochromatosis: Cut-off and Biopsy PatternCut-off · Lecture 46 · slides 100, 103–104

PrimarySecondary
Cause (slide 100)Autosomal recessive: mutated genes that control iron absorptionExcessive iron supplementation, chronic liver disease, anemia
Liver biopsy (Prussian blue)Hepatic accumulation of iron sparing the Kupffer cells until later in the diseaseIron (parenteral iron overload) predominantly in Kupffer cells
Treatment (slide 104)Therapeutic phlebotomy, ferritin-guided follow-upTreat the cause; chelation when phlebotomy is unsuitable
IRON PANEL CUT-OFF (slide 103)
No iron overloadFerritin <300 micrograms/L AND transferrin saturation <45%
Ferritin is an acute phase reactant: be cautious and look at the entire lab picture (slide 103).
Memory aid

300 and 45: under both and the tank is not overfull. Primary Passes over the Kupffer cells; Secondary Stuffs them.

300 ferritin <300 micrograms/L45 transferrin saturation <45%Both both under = no iron overloadPasses primary: Kupffer cells spared until lateStuffs secondary: iron mainly in Kupffer cells

Sideroblastic Anemia: TypesClassification · Lecture 46 · slides 29–30, 32

TypeSlide wording
HereditaryUsually X-linked
AcquiredUsually with myelodysplastic syndrome
Acquired / reversibleAlcohol; drugs (isoniazid, chlorambucil); copper deficiency; hypothermia; lead poisoning
MODERN CLASSIFICATION (slide 30)
Two categoriesDyserythropoiesis (hypohepcidinemia); transfusion-dependence (myelodysplastic syndrome, thalassemia)
Defining feature (slide 32): ring sideroblasts on bone marrow aspirate (iron-containing mitochondria in a ring around the nucleus); excess total body iron with increased serum iron, transferrin saturation and ferritin.
Memory aid

The reversible kind: A Drunk Copper Has Lead.

A AlcoholDrunk Drugs: isoniazid, chlorambucilCopper copper deficiencyHas hypothermiaLead lead poisoning

Where it breaks: Covers the reversible list only; hereditary = X-linked, acquired = myelodysplastic syndrome.

Erythropoietin: FDA-Approved IndicationsCriteria · Lecture 46 · slide 26

ItemSlide wording
FirstTreat the underlying condition (the slide’s arrow: “most important”)
AgentErythropoietin supplementation (epoetin alfa, Procrit)
HemoglobinLess than 10 g/dL
Anemia due toRheumatoid arthritis, inflammatory bowel disease, hepatitis C, zidovudine therapy in human immunodeficiency virus (HIV)-infected patients, myelosuppressive chemotherapy of solid malignancy, chronic kidney disease
May require parenteral iron; referral to hematology is not usually needed for anemia of chronic disease.
Memory aid

Under Ten, a Real Inflammation Hurts: Zidovudine, Chemo, Kidneys.

Ten hemoglobin <10 g/dLReal rheumatoid arthritisInflammation inflammatory bowel diseaseHurts hepatitis CZidovudine zidovudine therapy in HIVChemo myelosuppressive chemotherapy of a solid malignancyKidneys chronic kidney disease

Iron Therapy: the Response TimelineCut-off · Lecture 46 · slides 18–21

WhenExpected
3 weeksHematocrit back halfway toward normal
2 monthsFull return to baseline
3–6 months moreContinue iron after normal values return, to replenish iron stores
Not respondingHematology referral if the diagnosis is not confirmed or there is no response to oral iron (slide 17); parenteral iron if intolerant or refractory (most need 1–1.5 g, slide 21)
Ferrous sulfate 325 mg (66 mg elemental iron) once daily or every other day; constipation, so always give at least a prn laxative or stool softener; food reduces side effects but also absorption. Alternate-day dosing is probably best; or ferrous sulfate 44 mg/5 mL (as elemental iron) once daily in the morning, on an empty stomach with a full glass of orange juice (slides 18–19).
Memory aid

Halfway in 3 weeks, home in 2 months, then 3–6 months to restock the pantry.

Halfway hematocrit halfway to normal by 3 weeksHome baseline by 2 monthsRestock continue 3–6 months after normal to refill stores

Cytopenias Across the LifespanPopulations · Lecture 46 · slide 105

PopulationWhat changes clinically / care priority
InfantsUse neonatal complete blood count ranges; recognize inherited anemias and abnormal newborn screens; coordinate pediatric hematology
ChildAssess diet and inherited anemia; consider rare genetic or transfusion-related iron overload; weight-based treatment
AdolescentHeavy menses: check complete blood count and ferritin, treat iron deficiency and control bleeding; support adherence and transition to adult care
AdultEvaluate gastrointestinal or gynecologic blood loss, pregnancy and chronic kidney disease; HFE hemochromatosis usually presents in adults: screen family
ElderlyCheck iron and B12 deficiency, chronic kidney disease, drugs and marrow disorders (myelodysplastic syndrome); tailor to function, comorbidities and goals
Memory aid

Screens, Spoons, Periods, Pregnancy, Pills.

Screens infants: newborn screens, neonatal rangesSpoons child: diet, weight-based dosingPeriods adolescent: heavy mensesPregnancy adult: also blood loss, kidney disease, HFEPills elderly: drugs, plus iron/B12, kidney, myelodysplastic syndrome

Anemia: Follow-up and PrognosisFollow-up · Lecture 46 · slide 106

ConditionPatient education / referralPrognosis
Iron deficiencyIdentify blood loss; reinforce iron use; gastrointestinal referral if indicatedUsually resolves once the cause and iron stores are corrected
Chronic diseaseTreat inflammation; monitor blood count and iron; coordinate careCan persist while the underlying disease is active
SideroblasticRemove triggers; refer if the cause is unclear or transfusions are neededVariable; clonal forms may require continued follow-up
MegaloblasticTreat B12 or folate deficiency; monitor neurologic recoveryCounts improve; delayed B12 treatment may leave deficits
AplasticUrgent hematology; infection and bleeding precautions; discuss therapyDepends on severity and response to treatment
Renal (chronic kidney disease)Monitor hemoglobin, iron and blood pressure; refer for an erythropoiesis-stimulating agent or advanced diseaseOften chronic; may improve with iron or an erythropoiesis-stimulating agent
Aplastic anemia (slide 55): five-year survival >75% after a bone marrow transplant from a suitable donor; most untreated patients die within one year.
Memory aid

Fix it and it Fades (iron, megaloblastic); it Follows its disease (chronic disease, renal); it Depends (sideroblastic, aplastic).

Fades iron deficiency resolves; megaloblastic counts improve (late B12 may leave deficits)Follows chronic disease persists while active; renal often chronicDepends sideroblastic variable; aplastic depends on severity and response

Hemolysis & Iron Overload: Follow-upFollow-up · Lecture 46 · slide 107

ConditionPatient education / referralPrognosis
Sickle cellVaccines, fever and chest pain precautions, hematology follow-upLifelong; prevention reduces complications
ThalassemiaHematology for severe forms; iron monitoring; genetic counselingTrait often mild; severe forms need lifelong monitoring
G6PD deficiencyAvoid oxidative triggers; seek care for jaundice or dark urineUsually favorable with trigger avoidance
Autoimmune hemolysisTreat the cause; monitor relapse and thrombosis; hematology careRelapse may occur; depends on cause and response
HemochromatosisIron monitoring and phlebotomy; family screening; avoid excess ironEarly care limits injury; established cirrhosis may persist
Memory aid

Shots, Genes, Triggers, Clots, Bleeds.

Shots sickle cell: vaccinesGenes thalassemia: genetic counselingTriggers G6PD: avoid oxidative triggersClots autoimmune hemolysis: watch relapse and thrombosisBleeds hemochromatosis: phlebotomy

ECOG Performance StatusScore · Lecture 49 · slide 10 ★

GradeDescription of patient
0Fully active, able to carry on all predisease performance without restriction
1Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work
2Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours
3Capable of only limited self-care; confined to bed or chair more than 50% of waking hours
4Completely disabled; cannot carry on any self-care; totally confined to bed or chair
5Dead
ECOG (Eastern Cooperative Oncology Group; the slide’s picture credits “Eastern Clinical Oncology Group”). Prognosis is often dictated by fitness, particularly in older patients; ECOG is frequently part of clinical trial entry criteria (slide 10).
Memory aid

Count down the day: 0 Normal, 1 Office work, 2 Self-care but no work (up more than half the day), 3 In bed more than half the day, 4 In bed all day, 5 Dead.

0 Normal fully active, no restriction1 Office no strenuous activity, light or sedentary work2 Up >50% all self-care, no work, up and about more than 50% of waking hours3 Bed >50% limited self-care, bed or chair more than 50% of waking hours4 Bed all day completely disabled5 dead

Where it breaks: The 50% line is about waking hours, and it splits 2 (up) from 3 (in bed or chair).

Blast Thresholds: ALL, AML, MDS and CMLCut-offs · Lecture 49 · slides 25, 38, 47, 62 ★

DiseaseBlast cut-off on the slide
Acute lymphoblastic leukemiaDefined by blast cells of lymphoid origin ≥ 20% in bone marrow (slide 25)
Acute myeloid leukemiaBlast cells of myeloid origin; historically ≥ 20%; new guidelines: certain genetic mutations may allow the diagnosis with only 10% or higher (slide 38)
Myelodysplastic syndromeHigher risk MDS may have blasts but < 20% (otherwise AML) (slide 47)
CML chronic phaseNo or few blasts (<5%) (slide 62)
CML accelerated phaseOften 10–19% blasts (slide 62)
CML blast phase/crisisNo number on the slide: behaves as an acute leukemia, usually AML-like (slide 62)
Said aloud: “20% or more for leukemias, remember that”, and the drill “10%? No. 15%? No.” She also described chronic phase as “five to 6% blast” and blast phase as “greater than 20%”: learn the slide wording; the slides give no phase for 5–9%.
Memory aid

Twenty is the line to Leukemia: at 20 it is acute leukemia, under 20 it is still MDS. CML climbs Five, Ten-to-Nineteen, then Blast.

Twenty ≥ 20% marrow blasts = ALL (lymphoid) or AML (myeloid)Under 20 higher-risk MDS (blasts < 20%)Ten (AML only) certain genetic mutations: AML at ≥ 10%Five CML chronic phase <5%Ten-to-Nineteen CML accelerated phase, often 10–19%Blast CML blast phase behaves like AML

Where it breaks: The blast phase has no number on the slide; the 5–9% gap has no phase.

AML Subtypes: FAB M0–M7Classification · Lecture 49 · slides 32–33

FABNameWhat the slides add
M0Undifferentiated AML
M1AML with minimal maturation
M2AML with maturation
M3Acute promyelocytic leukemia (APL)Discussed separately: DIC, ATRA + arsenic (slide 43)
M4Acute myelomonocytic leukemiaMore extramedullary involvement; gum hyperplasia (slides 33, 35)
M5Acute monocytic leukemiaMore extramedullary involvement; gum hyperplasia (slides 33, 35)
M6Acute erythroid leukemiaVery rare
M7Acute megakaryocytic leukemiaVery rare (slide 33 misspells it “myelokaryocytic”)
FAB = French-American-British: historically ~8 subtypes; the WHO (World Health Organization) now recognizes 18 (slide 33). Out loud: “You don’t have to know anything about this, really, except that you will hear a lot about APL.”
Memory aid

Count the cells as they mature: 0-1-2 = myeloblasts with no, little, then some maturation; 3 = Promyelocyte (APL); 4-5 = Monocytes (the Mouth: gums); 6 = Erythroid; 7 = megaKaryocyte, the last stop.

0-1-2 undifferentiated, minimal maturation, with maturation3 = Promyelocyte M3 APL4-5 = Mouth M4 myelomonocytic, M5 monocytic: extramedullary, gum hyperplasia6 = Erythroid acute erythroid leukemia, very rare7 = Last stop acute megakaryocytic leukemia, very rare

Philadelphia Chromosome and Other TranslocationsGenetics · Lecture 49 · slides 20, 27, 43, 52–57 ★

DiseaseGenetic lesion on the slideWhat it means
Acute lymphoblastic leukemia (adults)BCR-ABL, translocation of chromosomes 9 and 22 (Philadelphia chromosome): the most common adult mutationPh+ ALL: tyrosine kinase inhibitors + chemotherapy; Ph- ALL: pediatric-like regimens under 40 (slide 27)
Acute lymphoblastic leukemia (children)Hyperdiploidy (excess copies of a chromosome)Favorable prognosis
Acute lymphoblastic leukemia (1/3 of all ages)No chromosome abnormalitiesNeed mutation analysis; relatively favorable
Chronic myelogenous leukemiaHallmark BCR-ABL: fusion of chromosomes 22 and 9 → Philadelphia chromosome; BCR attaches to ABL1, a fusion protein enzyme that promotes proliferation and reduces apoptosisPCR for BCR-ABL1 confirms the diagnosis and monitors treatment; tyrosine kinase inhibitors (slides 56–57, 60, 63)
Acute promyelocytic leukemiaTranslocation of chromosomes 15 and 17: PML-RARA fusionATRA (all-trans-retinoic acid) + arsenic trioxide (slide 43)
Polycythemia veraJAK2 mutationPhlebotomy, hydroxyurea (slide 52)
Myelofibrosis; essential thrombocythemiaJAK-STAT pathway mutationsMyelofibrosis: JAK inhibitors (palliative); essential thrombocythemia: aspirin, hydroxyurea (slides 53–54)
Memory aid

Philadelphia is a 9-to-22 Bus with two stops: ALL (adults) and CML (the hallmark). APL rides the 15-17 to the Retinoic acid bar; the MPNs ride the JAK.

9-to-22 Bus BCR-ABL, t(9;22), the Philadelphia chromosomeStop: ALL most common adult ALL mutation; TKI + chemotherapyStop: CML the hallmark; PCR confirms and monitors15-17 APL, PML-RARA; ATRA + arsenicJAK JAK2 in polycythemia vera; JAK-STAT in myelofibrosis and essential thrombocythemia

Where it breaks: Hyperdiploidy (children, favorable) and the third of ALL with no chromosome change are not in the hook.

The Myeloproliferative Neoplasms ComparedComparison · Lecture 49 · slides 51–54

Polycythemia veraMyelofibrosisEssential thrombocythemia
Too muchRed blood cells (blood viscosity ↑)All mature myeloid lines, then marrow fibrosisPlatelets
MutationJAK2JAK-STAT; elevated cytokinesJAK-STAT; rarely inherited
PresentationFatigue, headaches, blurry vision; classic: pruritus with warm baths or showersFatigue; splenomegaly symptoms (pain, early satiety, bloating); night sweats, fever, weight lossMostly asymptomatic; clotting (headaches, fatigue, paresthesias, vision changes) or bleeding (acquired von Willebrand factor)
ComplicationsThrombosis, splenomegaly, bleedingSevere splenomegaly, portal hypertension, bleeding, secondary AMLClotting: CVA (stroke), MI
TreatmentPhlebotomy, hydroxyureaJAK inhibitors (palliative)Aspirin, hydroxyurea
PrognosisExcellent: ~14 years; leukemic transformation ~5%Most aggressive: low risk 10–15 years, high risk < 2 yearsExcellent: normal life span
AlsoHematologist; stop smokingHematologist at diagnosisHematologist; stop smoking
Memory aid

Red, Scar, Plate: Polycythemia makes Red cells and Itches in the shower; Myelofibrosis Scars the marrow and swells the spleen; Thrombocythemia piles up Platelets that clot (or bleed).

Red + Itch polycythemia vera: red cells, JAK2, pruritus after warm bath; phlebotomyScar myelofibrosis: fibrosis, splenomegaly, most aggressive; JAK inhibitors palliativePlate essential thrombocythemia: platelets, clot (CVA, MI) or bleed; aspirin, hydroxyurea

Where it breaks: Hydroxyurea is in both polycythemia vera and essential thrombocythemia; the survival numbers are not in the hook.

CML PhasesStaging · Lecture 49 · slide 62

PhaseBlastsFeaturesShare
Chronic (stable)No or few (<5%)Early proliferative phase; excellent prognosis85–90%
AcceleratedOften 10–19%May have dysplastic granulocytes and fibrosis; frequently significant splenomegaly~4–5%
Blast phase/crisisNo number on the slideBehaves as an acute leukemia, usually AML-like; unique chromosomal and mutational abnormalities; AML-like regimens, poor responses to TKIs~1–2%
Advanced CML (accelerated or blast phase) “has different considerations” (slide 63) and a median survival < 12 months (slide 65). Out loud she said chronic phase is “five to 6% blast” and blast phase “greater than 20%”: learn the slide wording.
Memory aid

Most stay Calm: Chronic is under 5 (and 85–90% of patients); Accelerated is Ten-to-nineteen with a big spleen; Blast crisis acts like AML and shrugs off the TKI.

Calm chronic phase, <5% blasts, 85–90%, excellent prognosisTen-to-nineteen accelerated, often 10–19%, splenomegalyActs like AML blast phase: AML-like regimens, poor TKI response, 1–2%

CML Response Milestones (BCR-ABL1)Cut-offs · Lecture 49 · slide 64 ★

MilestoneFailureWarningOptimalTFR
3 monthsN.A.> 10%< 10%N.A.
6 months> 10%1–10%< 1%N.A.
12 months> 1%0.1–1%< 0.1%N.A.
> 18 months> 1%0.1–1%< 0.1%< 0.01%
Every cell is the BCR-ABL1 level. TFR = treatment-free remission. Slide 63: major molecular response (MMR) for 2 years may allow stopping TKIs, but 50% recur; slide 66 words it “sustained major molecular remission x 2 years”. Out loud: the level is checked about every 3 months, and warning or failure means a change of TKI or a resistance-mutation test.
Memory aid

Ten, One, Point-one: the optimal level drops one log at each milestone (3, 6, 12 months), and Point-oh-one at 18 earns time off (TFR).

Ten 3 months: optimal < 10%One 6 months: optimal < 1%Point-one 12 and > 18 months: optimal < 0.1%Point-oh-one > 18 months: < 0.01% = treatment-free remission range

Where it breaks: Failure lags one step behind optimal (> 10% at 6 months, > 1% at 12 and > 18); there is no failure value at 3 months.

Rai Staging: Chronic Lymphocytic LeukemiaStaging · Lecture 50 · slide 10

Rai stageFindings
0Asymptomatic lymphocytosis
ILymphocytosis and lymphadenopathy
IILymphocytosis, lymphadenopathy, organomegaly*
IIILymphocytosis and anemia, with or without lymphadenopathy and/or organomegaly
IVLymphocytosis and thrombocytopenia, with or without lymphadenopathy, organomegaly, and/or anemia
*Organomegaly = hepatomegaly and/or splenomegaly. Rai is historical, describes prognostic groups, needs no advanced imaging (physical exam and labs), and may set the indication for treatment (symptomatic disease or rapid progression). The contemporary tool is the CLL International Prognostic Index, named on the slide without its items.
Memory aid

Count down the body from the blood: 0 Lymphs, I Lumps, II Liver or spleen, III Low red cells, IV Low platelets.

0 Lymphs lymphocytosis onlyI Lumps + lymphadenopathyII Liver or spleen + organomegaly (hepatomegaly and/or splenomegaly)III Low red cells + anemia (nodes and organs optional)IV Low platelets + thrombocytopenia (anything else optional)

Where it breaks: Stages III and IV do not need the nodes or organs: anemia alone makes III, thrombocytopenia alone makes IV.

Chronic Lymphocytic Leukemia vs Monoclonal B LymphocytosisCut-off · Lecture 50 · slides 7–9

Chronic lymphocytic leukemiaMonoclonal B lymphocytosis
Absolute lymphocyte count> 5K x 3 months, or < 5K with lymphadenopathy or other symptoms; labs: “must be >5K; often >100K”Elevated but <5K lymphocytes
Nodes, organs, cytopenias, symptomsMay be presentAbsent (no lymphadenopathy, organomegaly, cytopenias, or other symptoms)
Confirm withFlow cytometry: clonal B cells; coexpression of CD19 and CD5; bone marrow biopsy usually not needed—
CourseRai 0–IV; Richter transformation riskProgresses to chronic lymphocytic leukemia at 1–2% per year
Neither slide says where exactly 5,000 falls; slide 7’s “must be >5K” sits against slide 8’s “< 5K with lymphadenopathy”. Other differentials (slide 9): atypical lymphocytosis with infections (pertussis); Waldenström macroglobulinemia, hairy cell leukemia, lymphomas in leukemic phase (told apart by morphology and immunophenotype).
Memory aid

Five thousand for three months, or Under five with a Finding (nodes or symptoms); no Finding under five is just MBL, which turns 1–2 a year.

Five thousand x three months ALC >5K for 3 months = chronic lymphocytic leukemiaUnder five with a Finding ALC <5K with lymphadenopathy or other symptoms = chronic lymphocytic leukemiaNo Finding under five monoclonal B lymphocytosis1–2 a year progression to chronic lymphocytic leukemia 1–2% per year

Where it breaks: Flow cytometry, CD19 and CD5 coexpression and the 100K figure are not in the hook.

Lymphoma Staging: Lugano (Modified Ann Arbor)Staging · Lecture 50 · slides 26, 40 (picture)

StagePicture caption
1Localized disease; single lymph node region or single organ
2Two or more lymph node regions on the same side of the diaphragm
3Two or more lymph node regions above and below the diaphragm
4Widespread disease; multiple organs, with or without lymph node involvement
The picture is titled “Stages of Non-Hodgkin’s Lymphoma” and is reused for Hodgkin lymphoma on slide 40: the same four stages apply to both. Staging needs imaging (usually CT or PET, slide 25). The Hodgkin treatment slide (41) adds “IIA”, “B symptoms” and “bulky”.
Memory aid

The diaphragm is the equator: One spot; Two on one side; Three on both sides; Four in the organs.

One spot single node region or single organOne side 2+ regions, same side of the diaphragmBoth sides 2+ regions above and below the diaphragmOrgans widespread, multiple organs, with or without nodes

Where it breaks: Nothing on the picture is left out; the IIA, B-symptom and bulky labels come from the Hodgkin treatment slide.

Non-Hodgkin Lymphoma: Treatment by TypeTreatment step · Lecture 50 · slide 27

PresentationTreatment
Single node, non-aggressiveRadiation
Low-grade B-cell lymphomasRituximab (anti-CD20 monoclonal antibody) if treatment required, ± chemotherapy if extensive
Aggressive B-cell lymphomasMulti-drug chemotherapy, e.g. R-CHOP: rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone; some get more aggressive regimens
T-cell lymphomasSimilar regimens (CHOP) minus rituximab: no CD20 on T cells
“Highly dependent on subtype and presentation.” Follicular lymphoma: frequently watch and wait, intermittent low-intensity therapy if symptomatic (slide 16).
Memory aid

R-CHOP is Really Cooking Very Dangerous Pasta; T cells skip the R.

Really rituximabCooking cyclophosphamideVery vincristineDangerous doxorubicinPasta prednisoneT cells skip the R T-cell lymphomas: CHOP without rituximab (no CD20)

Where it breaks: The hook follows the slide’s list order, not the letters of CHOP (in CHOP, H is doxorubicin and O is vincristine). Radiation for a single non-aggressive node and rituximab alone for low-grade B-cell lymphoma are not in the hook.

Non-Hodgkin Lymphoma: Poor-Prognosis FactorsPrognostic factors · Lecture 50 · slide 30

FactorSlide wording
AgeAge > 60
SpreadExtranodal sites
Performance statusPoor (>2) performance status, ECOG (Eastern Cooperative Oncology Group)
StageStage III or IV
LabElevated LDH (lactate dehydrogenase)
Same slide: indolent lymphomas incurable but survival often 10–15+ years (risk of progression to aggressive lymphoma); aggressive lymphomas often treatable and curable with chemotherapy (the slide’s “50% cured” was corrected out loud: “more closely to 70%”), 5-year survival 60–70%; T-cell lymphomas respond less well than B-cell.
Memory aid

A-E-P-S-L: an Aged patient, Extranodal, Poorly performing, Stage III-IV, with a high LDH.

Aged age > 60Extranodal extranodal sitesPoorly performing ECOG > 2Stage III or IVLDH elevated

Where it breaks: The survival figures in the note row are not in the hook.

Lymphoid Cancers: Genes, Translocations and InfectionsClassification · Lecture 50 · slides 5, 8, 16–18, 20–21, 31–32, 37, 39

MarkerDiseaseSlide wording
t(14;18), BCL-2Follicular lymphomaBCL-2 placed on chromosome 14, preventing cell death (slide 16)
Cyclin D1, t(11;14)Mantle cell lymphomaIdentifies the subtype (slide 20)
MYC upregulationBurkitt lymphomaStimulated cell growth and division (slide 31)
MYD88 mutation (~90%)Lymphoplasmacytic (Waldenström)Excess IgM → hyperviscosity (slide 18)
Del 13q, del 11q, trisomy 12, del 17pChronic lymphocytic leukemia80% of cases (slide 5)
CD19 + CD5Chronic lymphocytic leukemiaCoexpressed on the lymphocytes (slide 8)
CD15 + CD30Classical Hodgkin lymphomaExpressed (slide 39)
H. pyloriGastric MALT lymphoma2/3 of cases (slide 17)
Hepatitis CSplenic marginal zoneAssociated (slide 17)
HTLV-1Adult T-cell leukemia/lymphomaVery aggressive; Caribbean, Central and South America (slide 21)
Epstein-Barr virusEndemic Burkitt; HodgkinEndemic Burkitt strongly associated (slide 32); Hodgkin 40–50% (slide 37)
HIV/AIDSImmunodeficiency-associated BurkittAssociated (slide 32)
Memory aid

Follicles at Fourteen-Eighteen keep cells alive (BCL-2); the Mantle is Eleven-Fourteen with a Crown (cyclin D1); Burkitt's MYC Makes You Climb fast; Waldenström's MYD88 makes IgM Mud (hyperviscosity).

Fourteen-Eighteen follicular, t(14;18), BCL-2 blocks cell deathEleven-Fourteen + Crown mantle cell, t(11;14), cyclin D1Makes You Climb Burkitt, MYC upregulationMud lymphoplasmacytic, MYD88, IgM hyperviscosity

Where it breaks: The CD markers, the chronic lymphocytic leukemia deletions and the infection rows are not in the hook.

Hodgkin Lymphoma: Treatment by StageTreatment step · Lecture 50 · slide 41

StageTreatment
Early stage I and IIAShort course of chemotherapy (ABVD historically)
Bulky stage I or II disease, or B symptomsChemotherapy + radiation
Stage III or IVChemotherapy
ABVDAdriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine; new agents are replacing bleomycin because of pulmonary toxicities
Slide 41 is titled “Management of NHL” but sits in the Hodgkin section and teaches Hodgkin treatment. Relapse after first line: allogeneic stem cell transplant (slide 42).
Memory aid

Small and quiet: short chemo. Big or Burning (bulky or B symptoms): chemo plus Beams. Spread (III-IV): chemo. ABVD: A Big Vine Drops; Bleomycin hurts the lungs.

Small and quiet I and IIA: short chemotherapyBig or Burning bulky I-II or B symptoms: chemotherapy + radiationSpread III or IV: chemotherapyA Big Vine Drops doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine

Where it breaks: The transplant-at-relapse line (slide 42) is not in the hook.

Tumor Lysis SyndromeEmergency · Lecture 50 · slides 28, 33–34

Slide wording
WhatMedical emergency: rapid tumor breakdown releases potassium, phosphorus, uric acid
KidneyAcute renal failure from uric acid and calcium phosphate crystals in the renal tubules
Biggest riskHyperkalemia → arrhythmia and potential death
WhoSpontaneously in highly aggressive lymphoma (Burkitt); also acute lymphoblastic and acute myeloid leukemia with marked leukocytosis
TreatAggressive IV fluid hydration
PreventAnticipate in aggressive lymphoma: allopurinol (hypouricemic agent) and fluids in advance; “drink plenty of fluids and take allopurinol!” (slide 34)
Memory aid

Tumor lysis spills a PUP: Potassium, Uric acid, Phosphorus. Potassium Stops the heart, the crystals Stop the kidney; Flush and Fix with fluids and allopurinol.

PUP potassium, uric acid, phosphorus releasedStops the heart hyperkalemia → arrhythmia (largest risk)Stops the kidney uric acid and calcium phosphate crystals → acute renal failureFlush and Fix aggressive IV fluids; allopurinol ahead of time

Where it breaks: Who gets it (Burkitt spontaneously; acute leukemias with marked leukocytosis) is not in the hook.

Multiple Myeloma: CRAB and SLiMCriteria · Lecture 50 · slides 47, 48, 50, 52 ★

LetterFindingSlide wording
CCalcium (hypercalcemia)Constipation, increased thirst, urinary frequency, nausea
RRenal insufficiencySwelling
AAnemiaFatigue, shortness of breath
BBone lesions/painOften back, chest, or pelvis; osteolytic “punched out” lesions (slide 48)
SBone marrow plasma cellsPicture: “Bone marrow ≥ Sixty (60%) plasmacytosis”
LiAbnormal light chain ratioPicture: “Light chains >100:1”
MMRI lesionPicture: “MRI: ≥2 lesions”
Diagnosis (slide 50): ≥ 10% bone marrow plasma cells or biopsy-proven plasmacytoma + 1 or more CRAB feature. SLiM = “may be asymptomatic with certain lab findings” (slide 47), while slide 52 says myeloma is “by definition a symptomatic condition”. The picture also lists amyloidosis, hyperviscosity, polyneuropathies; higher risk of infections.
Memory aid

The CRAB is SLiM: CRAB pinches the body (Calcium, Renal, Anemia, Bone); SLiM shows on the labs (Sixty percent, Light chains 100 to 1, MRI 2 lesions).

C hypercalcemiaR renal insufficiencyA anemiaB bone lesionsSixty ≥60% marrow plasma cellsLight 100 light chain ratio >100:1MRI 2 ≥2 MRI lesions

Where it breaks: The symptoms under each CRAB letter and the “also” list (amyloidosis, hyperviscosity, polyneuropathies) are not in the hook.

MGUS vs Smoldering Myeloma vs Multiple MyelomaCut-offs · Lecture 50 · slides 44, 50, 53, 56, 57 ★

MGUSSmoldering myelomaMultiple myeloma
M-protein< 3 g/dL> 3 g/dL ANDMonoclonal protein on serum protein electrophoresis (characteristic)
Bone marrow plasma cellsClonal < 10%10–60%≥ 10% or biopsy-proven plasmacytoma
Myeloma-defining eventsNone; asymptomatic by definitionNone (anemia, bone lesions, renal failure, etc.)+ 1 or more CRAB feature
Progression~1% per year~10% per year; some high-risk groups >50% within 2 yearsRelapsing; incurable
Treatment—Typically none; early intervention for some subgroups3- or 4-drug regimen; autologous transplant if a candidate
Neither slide says where exactly 3 g/dL or 10% falls. Smoldering “10–60%” (slide 57) meets the SLiM picture’s “≥ 60%” (slide 47) at 60%. Slide 57’s “AND” is the slide’s (current International Myeloma Working Group wording: ≥3 g/dL or 10–60%). MGUS is printed “of unknown significance” on slide 56 (“undetermined” on the slide 44 picture).
Memory aid

Three and Ten are the gates, and the speed goes up by ten: under 3 and under 10 = MGUS, creeping 1% a year; over 3 and 10–60 = smoldering, 10% a year; 10 or more plus a CRAB = myeloma.

Under 3, under 10 MGUS: M-protein <3 g/dL, plasma cells <10%1% a year MGUS progressionOver 3, 10–60 smoldering: M-protein >3 g/dL and 10–60% plasma cells10% a year smoldering progression10 + CRAB myeloma: ≥10% plasma cells (or plasmacytoma) + 1 CRAB feature

Where it breaks: The high-risk smoldering group (>50% within 2 years) and the treatment row are not in the hook.

R-ISS Staging: Multiple MyelomaStaging · Lecture 50 · slide 51 (table picture)

StageCriteriaSurvival (mo)
Iβ2-microglobulin <3.5 mg/L; albumin ≥3.5 g/dL and standard-risk chromosomal abnormalities and normal LDH (defined as less than ULN)82
IINot R-ISS stage I or III62
IIIβ2-microglobulin ≥5.5 mg/L regardless of albumin levels and high-risk chromosomal abnormalities: del 17p, t(4;14) or t(14;16) and high LDH (defined as higher than ULN)40
R-ISS = Revised International Staging System; LDH = lactate dehydrogenase; ULN = upper limit of normal. Prognostic only: “does not impact treatment decisions broadly”. Slide 50 prints the test as “beta-2 macroglobulin”; it is beta-2 microglobulin. (Current guideline note: published stage III is β2-microglobulin ≥5.5 with high-risk abnormalities or high LDH; the slide prints “and”.)
Memory aid

3.5 and 3.5 is stage one; 5.5 with bad chromosomes and high LDH is stage three; everything in between is two.

3.5 and 3.5 stage I: β2-microglobulin <3.5 mg/L, albumin ≥3.5 g/dL, standard risk, normal LDH5.5 + bad chromosomes stage III: β2-microglobulin ≥5.5, del 17p, t(4;14) or t(14;16), high LDHIn between stage II: not I or III

Where it breaks: The survival months (82, 62, 40) are not in the hook.

★ Emphasized — Cytopenias and Hemochromatosis

TermWhat you need to know
What this card isFirst the slides Prof. Ward flagged out loud (recording, 12 November); then the slides’ own emphasis (bold, asterisks, underline, the slide 26 arrow). His rule: you are tested on what is on the slide.
★ Said: iron deficiency diagnosis“You guys want to know this slide”: microcytosis, hypochromia, ↓ ferritin, ↓ transferrin saturation, ↑ total iron-binding capacity (slide 15).
★ Said: chronic disease“Want to pay attention to this slide?”: interleukin 6 → ↑ hepcidin (slide 23).
★ Said: B12 vs folate“Definitely one that you guys want to pay attention to”: homocysteine up in both; methylmalonic acid up in B12 only (slide 47).
★ Said: treatment slidesAplastic anemia treatment (slide 58); sickle cell management (slide 98); hemochromatosis treatment, therapeutic phlebotomy (slide 104); the lifespan slide (slide 105).
★ Said: smearsGenetic hemolysis: upper smear = spherocytes (slide 75). G6PD: bite cells (left) and Heinz bodies (right); hemolysis is intravascular and extravascular (slides 77–78).
★ Said: thalassemia labs“Did I tell you guys to pay attention to slide 88?” (slide 88).
★ Said: acute chest“A chest x-ray is the first imaging study if you’re suspecting acute chest syndrome” (slide 94).
Played downLuspatercept (slide 33): “Sorry, don’t know that drug.” Chloroquine in G6PD: “don’t just assume all anti-malarial medications carry that same risk.”
★ Iron deficiencyChronic blood loss is the most common cause in adults (slide 10); asterisked: nail bed changes (koilonychia), cheilosis, Plummer-Vinson syndrome (slide 12).
★ Ferritin trapFerritin is an acute phase reactant: a normal or high ferritin does not exclude iron deficiency (slide 14).
★ Oral ironFerrous sulfate; side effect constipation (bold, underlined); the orange-juice preparation line is bold (slides 18–19).
★ Chronic diseaseTreat the underlying condition: arrowed “most important” (slide 26).
★ B12Pernicious anemia is the most frequent cause; burning to hands and feet; homocysteine and methylmalonic acid levels (slides 44, 45, 47).
★ HemolysisHaptoglobin; bilirubin, haptoglobin, lactate dehydrogenase; schistocytes; jaundice (slides 66–68, 70).
★ Autoimmune hemolysisIncreased risk of venous thromboembolism (slide 73).
★ G6PDFava beans; acute hemolytic anemia on oxidative stress (slide 79).
★ ThalassemiaImbalance in expression → accumulation and precipitation of globin subunits (slide 85); iron overload (slide 87).
Also boldSideroblastic microcytosis is variable (slide 32); microcytic vs macrocytic lab lists (slide 50).

Anemia: Definition & First Approach

TermWhat you need to know
AnemiaA reduction in healthy red blood cells or hemoglobin, decreasing oxygen delivery to the tissues (slide 6).
First stepsHistory and physical; complete blood count (all three cell lines, pancytopenia?); the MCV; the reticulocyte index for marrow response (slide 8).
All anemiasComplete blood count, reticulocyte count, reticulocyte index (slide 50).
MicrocyticSerum iron, transferrin saturation, total iron-binding capacity, ferritin, fecal occult blood test, urinalysis.
MacrocyticB12 and folate, smear, homocysteine and methylmalonic acid; for pernicious anemia anti-intrinsic factor and anti-parietal cell antibodies, parenteral B12 trial.

Iron Deficiency Anemia

TermWhat you need to know
CausesChronic blood loss (gastrointestinal, menses; most common in adults); diet (vegan, tea, calcium antacids, proton pump inhibitors); malabsorption (gastric bypass, celiac sprue, food allergies); demand (pregnancy, growth in infancy or adolescence).
Who50% of anemia worldwide; ~1 million deaths a year (71% Africa and Asia). United States: men under 50 1%, women of childbearing age 10%, 9% of children 12–36 months (1/3 of them anemic); low-income families at risk.
SignsFatigue, pallor, exercise intolerance, dyspnea on exertion, smooth tongue, pica (common), koilonychia (spoon nails), cheilosis, Plummer-Vinson syndrome.
DifferentialAnemia of chronic disease, thalassemia, lead poisoning, zinc deficiency, sideroblastic anemia.
DiagnosisMicrocytosis (MCV <80), hypochromia (↓ MCH); ↓ ferritin, ↓ transferrin saturation, ↑ total iron-binding capacity; microcytic hypochromic smear. Also urinalysis, fecal occult blood (stool guaiac), consider prothrombin and partial thromboplastin times.
TreatThe cause: oral contraceptive (consider continuous-cycle) for menses; gastrointestinal bleed → colonoscopy or endoscopy for colorectal cancer; stop anticoagulants if severe (consult cardiology). Then iron replacement.
ParenteralIf intolerant or refractory; over 15 minutes to 1 hour. Ferric pyrophosphate citrate (Triferic) goes in the dialysate to replace the 5–7 mg lost per hemodialysis.

Anemia of Chronic Disease (Inflammation)

TermWhat you need to know
CauseAny inflammatory condition: infection, autoimmune, neoplasm. Interleukin-6 → hepcidin ↑ blocks iron absorption; inflammation inhibits renal erythropoietin; direct marrow suppression.
Who2nd most common anemia; any age; older adults at increased risk (~1 million over 65 in the United States).
PictureInitially resembles iron deficiency; symptoms like iron deficiency plus the causative condition.
DiagnosisSame labs as iron deficiency; erythrocyte sedimentation rate and/or C-reactive protein if inflammation not apparent; ferritin normal or increased; ferritin <30 ng/mL = coexistent iron deficiency.
TreatThe underlying condition; erythropoietin if indicated (hemoglobin <10); maybe parenteral iron; hematology usually not needed.

Sideroblastic Anemia & Lead Poisoning

TermWhat you need to know
WhoRare; about 2/3 males in early childhood or adolescence, 1/3 young to middle-aged females; any age.
PictureNothing specific beyond anemia; usually moderate, hematocrit 20–30%.
DiagnosisVariable microcytosis; dimorphic smear (microcytic, normal and macrocytic cells); ↑ serum iron, transferrin saturation, ferritin; zinc ↑ if from copper deficiency; ring sideroblasts on marrow aspirate = defining.
TreatRemove the agent; transfusion if severe; poor response to erythropoietin; occasional response to pyridoxine (50–200 mg/day); luspatercept for myelodysplastic syndrome with ring sideroblasts; hematology for diagnosis or transfusion.
Lead (plumbism)Microcytic hypochromic anemia with basophilic stippling (abnormal nucleic acid collections). Sources: industrial, gasoline sniffing, lodged bullets, lead cookware, paint chips, Flint water.
Lead effectsNeurologic most vulnerable (irritability, behavior change, peripheral neuropathy); abdominal colic, nausea, constipation; lead line in the gums.
Lead treatmentStop exposure; by lead level; severe with neurologic effects → chelation: succimer (Chemet), dimercaprol, ethylenediaminetetraacetic acid (EDTA).

Macrocytic, Megaloblastic & Folate

TermWhat you need to know
MacrocyticMCV >100: megaloblastic (B12, folate) or non-megaloblastic (alcohol or drug, hypothyroidism, liver failure, marrow dysplasia; usually <115).
SmearMacro-ovalocytes and hypersegmented neutrophils (slides 39–40).
Folate causesDiet (impoverished, alcohol use disorder, elderly); pregnancy; proximal small bowel malabsorption; drugs: methotrexate, 5-fluorouracil, hydroxyurea, phenytoin, metformin.
Folate replacementFolic acid 1 mg orally or parenterally daily for 1–2 weeks, after checking for B12 deficiency.

Vitamin B12 & Pernicious Anemia

TermWhat you need to know
AbsorptionPeptic digestion frees B12 → intrinsic factor from parietal cells binds it → binds cubilin in the distal ileum → transcobalamin → stored in the liver (~3–4 years or more).
Pernicious anemiaMost frequent cause of B12 deficiency: autoimmune attack on parietal cells and/or intrinsic factor → gastric atrophy and increased gastric cancer risk.
ClinicalAnemia findings; glossitis, oral ulcers. Distinguishing: neurologic (dorsal and lateral cord demyelination): neuropsychiatric change, stocking-and-glove numbness, tingling, burning of the hands and feet, then unsteady gait and lost position sense; may not improve with B12.
ReplacementB12 1000 mcg subcutaneously or intramuscularly weekly for 3 weeks; or oral cobalamin 1000–2000 mcg daily.

Chronic Kidney Disease & Aplastic Anemia

TermWhat you need to know
Kidney: orderComplete blood count, reticulocytes, ferritin and transferrin saturation; assess other causes (slide 53).
Kidney: treatCorrect iron deficiency; oral or intravenous iron and an erythropoiesis-stimulating agent by stage, hemoglobin and risk; monitor hemoglobin, iron and blood pressure; nephrology for advanced disease.
Aplastic: whatPancytopenia from loss of hematopoietic stem cells (the defining feature).
Aplastic: whoHalf in the first three decades (peaks in childhood and at 20–25); male:female ~1:1; 0.6–6.1 per million.
Aplastic: causesAutoimmune; stem cell injury (cytotoxic drugs, chloramphenicol, ionizing radiation, benzene, pesticides); viruses; clonal (paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, acute myeloid leukemia); inherited (Fanconi anemia, childhood).
Aplastic: pictureRecurrent infections (neutropenia), bleeding, petechiae, purpura (thrombocytopenia), fatigue, pallor.
Aplastic: planBone marrow biopsy required; urgent hematology/oncology; treatment = bone marrow transplant.

Leukopenia & Neutropenia

TermWhat you need to know
CausesViral illness, medications or chemotherapy, autoimmune disease, nutrient deficits, marrow pathology.
WorkupRepeat complete blood count with differential, trend, peripheral smear, other cell lines.
Chronic careStop an offending drug; correct deficiencies; selected patients need G-CSF (granulocyte colony-stimulating factor).
TeachReport fever or rigors promptly; monitor counts.
PrognosisTransient viral leukopenia often resolves; persistent or severe neutropenia = more infection risk, may mean marrow disease.

Hemolytic Anemias & Autoimmune Hemolysis

TermWhat you need to know
DefinitionShortened red cell survival from premature destruction. Red cell ~6 µm vs capillaries ~2 µm.
Red cell defensesDeformable membrane and cytoskeleton (spectrin, ankyrin); strong redox environment; biconcave disc (~40% more surface area).
All hemolytic anemias↓ red cell life span, compensatory ↑ erythropoiesis, retention of breakdown products (iron); marrow hyperplasia and ↑ reticulocytes; extramedullary hematopoiesis (liver, spleen, lymph nodes) if severe and chronic.
RoutesExtravascular (more common; spleen and liver macrophages → unconjugated bilirubin); intravascular (free hemoglobin → haptoglobin; some into urine).
PresentationAnemia symptoms; severe: chest pain, high-output heart failure, shock. Differentiating: jaundice, splenomegaly, joint pain, hematuria.
AutoimmuneAntibody against the red cell membrane; primary (de novo, almost always IgG) or secondary; transfusion reaction. Coombs positive; venous thromboembolism risk.

G6PD Deficiency

TermWhat you need to know
WhatMost common genetic disorder of erythrocytes (200–400 million); X-linked recessive, so generally only males are affected; carrier females generally unaffected.
MechanismNo reduced glutathione → oxidative damage → Heinz bodies inside the cell; splenic macrophages bite out a chunk (bite cells); intravascular and extravascular hemolysis.
PrevalenceKurdish Jews 60–70%; Sardinians 4–35%; Nigerians 22%; Thai 17%; American Black people 11–12%; Japanese and Koreans 0–1%.
SymptomsNone until oxidative stress; then abdominal pain, jaundice, dark urine, splenomegaly.
Treat“Don’t eat that” (avoid the trigger); hydrate; transfuse if needed; splenectomy only for recurrent attacks.

Thalassemia

TermWhat you need to know
WhatMutations cut alpha or beta globin synthesis; most erythroblasts die in the marrow; globin imbalance → subunits precipitate → destruction in the spleen.
CourseHemolytic anemia, iron overload, splenomegaly, extramedullary hematopoiesis, jaundice, skeletal changes (pictured on slide 87).
TreatSupportive: transfusion only when absolutely necessary (worsens iron overload); folic acid; genetic counseling; preconception testing with a family history.

Sickle Cell Disease

TermWhat you need to know
ClinicalAnemia almost universal, hematocrit 15–30%; pain crises (microvascular occlusion: pain, tenderness, anxiety, tachycardia).
InfarctionSplenic infarct; aseptic necrosis of the femoral or humeral heads; retinopathy; kidney disease; leg ulcers; priapism; susceptibility to encapsulated bacteria.
StrokePediatric stroke 300× unaffected children; 25% have a stroke by age 45.
Acute chest syndromeLeading cause of death; often with a pain event; >10% adult mortality; infection, infarction, pulmonary or fat embolism; chest pain, fever, dyspnea, hypoxemia, pulmonary infiltrates on a chest X-ray.
ManagementHydroxyurea raises HbF and reduces vaso-occlusive events; vaccines and childhood penicillin prophylaxis; transfusion or exchange for selected severe events; red flags: fever, chest pain or hypoxemia, new neurologic deficit.

Hemochromatosis

TermWhat you need to know
WhatIron overload: excess deposition → oxidative stress, fibrosis, organ dysfunction; asymptomatic early. Liver, heart, joints, endocrine organs, skin.
SignsFatigue; skin bronzing (face, neck, groin, extensor forearms and lower legs); joint pain, 2nd and 3rd metacarpophalangeal joints and knees; cardiomyopathy.
PearlPituitary iron → hypogonadotropic hypogonadism: low libido, impotence, amenorrhea, small testes, gynecomastia, less body hair.
FamilyConsider HFE testing with elevated transferrin saturation or ferritin; offer first-degree relative screening.
TeachAvoid iron supplements and excess alcohol. Early treatment prevents organ damage; assess fibrosis, monitor cirrhosis for liver cancer.

★ Emphasized — Hematologic Malignancies Part I

TermWhat you need to know
What this card isFirst what Prof. Gannon flagged out loud (recording, 18 November); then the slides’ own emphasis (bold, underline). She gave few explicit cues and no “on the exam” line.
★ Said: Auer rods“Highlight, star, underline ... Auer rods ... pathognomonic for AML” (slides 31, 36). Auer rods are fused lysosomes; they confirm a myeloid leukemia.
★ Said: 20% blasts“Write this down ... 20% or greater blast in the bone marrow” diagnoses leukemia (slides 25, 38); MDS blasts stay < 20% (slide 47).
★ Said: BCR-ABL in ALL“Star, highlight, underline ... ALL is associated with this BCR-ABL mutation ... chromosome nine and 22” (slide 20).
★ Said: Reed-Sternberg“If you’re ever taking a test and you see a Reed Sternberg cell ... Hodgkin lymphoma” (slide 15).
★ Said: B symptoms“Make sure you’re writing down what are B symptoms”: fevers, night sweats, weight loss (slides 15, 22).
★ Said: hematopoiesis“Ingrain this in your brains”: stem cell → myeloid (megakaryocyte/platelets, eosinophil, basophil, erythrocytes, monocyte, neutrophil) and lymphoid (T, B, NK; B → plasma cell) (slide 5).
★ Said: ALLBimodal: children, then older adults (slide 18); lumbar puncture, “the big one”: CNS leukemia is common in ALL (slides 23, 25).
★ Said: APL“Bleeding, DIC, coagulopathy, and that it does not need chemotherapy. ATRA and arsenic” (slide 43).
★ Said: testsBone marrow biopsy and flow cytometry = “your backbone testing” (slide 36). JAK2 in polycythemia vera, “you may come across this on your testing” (slide 52). ECOG matters for treatment (slide 10).
★ Said: CML milestonesOptimal BCR-ABL1 < 10% at 3 months, < 1% at 6, < 0.1% at 12 (slide 64).
Played downFAB subtypes except APL (slide 33); secondary-AML subgroup modifiers (slide 38); protocol pictures (slides 26, 39, a joke); flow markers; TKI side effects (slide 63).
Slides underlineBone marrow biopsy and/or flow cytometry (slides 11, 23, 36); most common malignancy under 15 = ALL (slide 18); Auer rods confirm myeloid etiology (slide 36); splenomegaly in CML (slide 59); bone marrow biopsy and PCR for BCR-ABL1 (slide 60).
Slides boldPh+ ALL = TKI + chemotherapy (slide 27); secondary AML = poor outcome (slides 32, 38); gum involvement in M4/M5 (slide 35); fit 7+3 vs unfit low-intensity, allogeneic transplant IF remission (slide 40); MDS: ESA for low risk + anemia, only cure = allogeneic transplant (slide 48); PV pruritus with warm baths (slide 52); ET aspirin, hydroxyurea (slide 54); CML now largely chronic (slide 56).

Hematopoiesis & the Malignancy Families

TermWhat you need to know
ClonalityOne oncogenic mutation in a single somatic cell gives a clonal advantage; the clone expands and gathers more alterations (slide 6).
DefinitionCancers of blood-forming tissues or the lymphatic system from a monoclonal hematologic clone; leukemias, lymphomas, plasma cell disorders; cell of origin sets the type (lymphoid or myeloid) (slide 7).
Acute vs chronicAcute = immature progenitor white cells, rapid proliferation; chronic = mature malignant white cells. Crowding causes anemia, thrombocytopenia, most commonly leukocytosis (slide 14).
LymphomaLymphoid tissue (nodes, spleen, thymus); >100 subtypes; non-Hodgkin 90% (B and T cell), Hodgkin 10% (few Reed-Sternberg cells among immune cells); lymphadenopathy, night sweats, weight loss, fevers (slide 15).
MyelomaPlasma cells (terminally differentiated B cells); one monoclonal antibody, the M protein; CRAB: hypercalcemia, renal dysfunction, anemia, bone pain; infections (slide 16).
Epidemiology9.4% of new United States cancers (2025); ~1.8 million living with one; 9.1% of cancer deaths (slide 8).
Risk factorsRadiation, benzene; family history, trisomies; autoimmune disorders; older age (exceptions: ALL, some lymphomas) (slide 9).
PresentationNon-specific: fatigue (anemia), bleeding (thrombocytopenia), swollen nodes (lymphoma), bone pain (myeloma); incidental cytopenias or high protein (myeloma). Almost all need bone marrow biopsy and/or flow cytometry (slide 11).
TransplantHSCT = bone marrow transplant, after high-dose chemotherapy +/- radiation. Allogeneic = donor cells; autologous = own cells (“stem cell rescue”) (slide 12).

Acute Lymphoblastic Leukemia (ALL)

TermWhat you need to know
WhatLymphoid progenitor/stem cell leukemia; very immature, rapidly proliferating; B-cell precursor (leukemic, marrow) or T-cell (rarer, lymphoma-like, thymus, mediastinal mass); lymphoblastic lymphoma subtype (slides 18–19, 22).
WhoBimodal: most common malignancy under 15 (5-year survival >90%); adult peak ~50, poor over 40. Slide 21: children under 5, adults over 50; male (slides 18, 21).
Risk factorsRadiation (atomic bomb, prior treatment); benzene, chemotherapy; EBV, HTLV-1 (Caribbean); Down syndrome, Fanconi anemia; male (slide 21).
GeneticsChildren: hyperdiploidy, favorable. Adults: BCR-ABL t(9;22) (Philadelphia). 1/3: no chromosome change, relatively favorable (slide 20).
SignsAnemia, bleeding (petechiae, purpura), infections, B symptoms, >50% lymphadenopathy/hepatomegaly/splenomegaly, bone or joint pain. White count often > 30K (30% neutropenic) (slide 22).
DiagnoseFlow cytometry (B or T) + bone marrow biopsy; imaging, labs, lumbar puncture. Lymphoid blasts ≥ 20% in marrow; diffuse marrow and blood involvement (aggressive lymphomas spare the marrow); CNS involvement = adverse (slides 23, 25).
DifferentialAML, CLL, aggressive lymphomas, hairy cell leukemia; lymphoblastic lymphoma (treated alike); atypical lymphocytosis of mononucleosis, pertussis (not clonal on flow) (slide 24).
TreatPh-: pediatric-like regimens under 40 (induction, consolidation, maintenance). Ph+: TKI + chemotherapy. Allogeneic transplant for adverse risk or relapse (slide 27).
OutcomeUnder 15: ~90% five-year survival, 2–5 years of chemotherapy; adults ~40%. Hematologist/oncologist, admission, life-long surveillance, trials (slides 28–29).

Acute Myeloid Leukemia (AML) & APL

TermWhat you need to know
WhatMyeloid progenitor/stem cell leukemia; Auer rods pathognomonic; mostly over 60; unusual in children outside neonates (slide 31).
Risk groupsFavorable, intermediate, poor. Secondary AML (from MDS, MPN, or after other cancer therapy) = poor outcomes (slides 32, 38).
Risk factorsPrior high-dose radiation; benzene, petroleum, alkylators; HIV; Down syndrome, Fanconi anemia; over 60; male (slide 34).
SignsAnemia, bleeding, infections, B symptoms; M4/M5: gum hyperplasia, extramedullary disease. White count usually high; > 200K rare; > 100K = emergent leukapheresis (slides 33, 35).
DiagnoseFlow cytometry (vs ALL) + bone marrow biopsy; Auer rods confirm myeloid; mutation sequencing. Myeloid blasts ≥ 20% (10% with certain mutations) (slides 36, 38).
DifferentialALL, CML, MDS, myeloproliferative disorders; pancytopenia of infection, aplastic anemia, nutritional deficiency, drugs (slide 37).
TreatFit: 7+3 (cytarabine + anthracycline). Unfit: hypomethylating agents +/- venetoclax (BCL-2 inhibitor). Allogeneic transplant for intermediate/high risk once in remission (slide 40).
OutcomeRelapse common; 48% at 1 year, 25–30% at 5; favorable risk ~2/3; over 70: 5%; adverse or secondary ~10% (slide 41).
APL (M3)Arrest at the promyelocyte; t(15;17) PML-RARA; DIC and bleeding, high early mortality; arsenic trioxide + ATRA; >90% cure if the presentation is survived (slide 43).

Myelodysplastic Syndrome (MDS)

TermWhat you need to know
WhatMyeloid malignancies defined by dysplasia (abnormal-appearing myeloid cells); from clonal hematopoiesis; hypercellular marrow, cells not functional (slides 45–46).
WhoOlder (median 70), men; often idiopathic; sometimes prior chemotherapy or radiation (slide 46).
PictureCytopenias, most often anemia; many asymptomatic, found incidentally; abnormal neutrophils; multinucleated red cells; higher risk: blasts < 20% (otherwise AML) (slide 47).
TreatLow risk + anemia: ESA (erythropoiesis-stimulating agents) + transfusions; neutropenia: myeloid growth factors (careful); higher risk: chemotherapy or hypomethylating agents; only cure = allogeneic transplant (slide 48).
OutcomeLower risk: median survival > 5 years. Very high risk: median overall survival 9 months, > 80% AML within 5 years. Low risk goal: quality of life (slide 49).

Myeloproliferative Neoplasms: PV, MF, ET

TermWhat you need to know
WhatRare myeloid malignancies with atypical proliferation of mature cell lines (slide 51).
Polycythemia veraJAK2; red cells ↑, viscosity ↑; fatigue, headaches, blurry vision; pruritus with warm baths or showers; thrombosis, splenomegaly, bleeding; phlebotomy, hydroxyurea; ~14 years, ~5% leukemic; hematologist, stop smoking (slide 52).
MyelofibrosisJAK-STAT, cytokines ↑, all myeloid lines ↑, then marrow fibrosis; splenomegaly (pain, early satiety, bloating), night sweats, fever, weight loss; most aggressive MPN; portal hypertension, secondary AML; JAK inhibitors, palliative; 10–15 years low risk, < 2 high risk (slide 53).
Essential thrombocythemiaJAK-STAT; platelets ↑; mostly asymptomatic; clotting (headache, paresthesias, vision changes) or bleeding from acquired von Willebrand factor loss; CVA, MI; aspirin, hydroxyurea; normal life span; stop smoking (slide 54).

Chronic Myelogenous Leukemia (CML)

TermWhat you need to know
WhatStem cell leukemia making excess granulocytes (more mature than blasts); historically to acute leukemia in ~4–6 years; BCR-ABL / Philadelphia chromosome hallmark; now largely chronic (slide 56).
Mechanismt(9;22): BCR attaches to ABL1; the fusion enzyme drives proliferation, blocks apoptosis: the cell “can’t turn off” (slide 57).
Who15–20% of leukemias; median age 45–55; slightly more men; radiation bomb victims; no other risk factors (slide 58).
Signs~50% asymptomatic (leukocytosis on a blood count); fatigue; splenomegaly (abdominal swelling); B symptoms. White count often > 100K (to 500K), platelets high, anemia, very low blasts (slide 59).
DiagnoseBone marrow biopsy + PCR for BCR-ABL1; PCR in a patient with marked granulocytosis confirms and later monitors; marrow: granulocytic proliferation, myelocytes (slide 60).
DifferentialMyelofibrosis (CML: normal red cell shape, normal hematocrit; BCR/ABL1+). Reactive leukocytosis: no splenomegaly, white count usually < 50K, BCR/ABL1 negative (slide 61).
TreatTyrosine kinase inhibitors (6 agents) for chronic phase; stop after MMR for 2 years (50% recur, most recapture); allogeneic transplant for young healthy patients with TKI resistance or advanced disease (slides 63, 65).
OutcomeMost live normal lives on TKIs; accelerated or blast phase median survival < 12 months; hematologist; treatment for life unless sustained remission x 2 years; trials for advanced phase (slides 65–66).

Ages & Populations (Lecture 49)

TermWhat you need to know
ChildrenALL: most common malignancy under 15, peak under 5, hyperdiploidy favorable, ~90% survive; AML unusual outside neonates (slides 18, 20–21, 28, 31).
AdultsALL second peak ~50, poor over 40; CML median 45–55 (slides 18, 58).
ElderlyFitness (ECOG) drives prognosis; AML over 60, unfit → low-intensity therapy, over 70 only 5% at 5 years; MDS median 70 (slides 10, 31, 40–41, 46).

★ Emphasized — Hematologic Malignancies Part II

TermWhat you need to know
★ Said: CRAB“You absolutely need to know this ... it will 100% be on a test”: hypercalcemia, renal insufficiency, anemia, bone lesions (slide 47).
★ Said: 10% plasma cellsMyeloma needs only ≥10% marrow plasma cells (+ 1 CRAB), unlike the 20% blasts of acute leukemia: “remember that for your test” (slide 50). Remember Bence Jones protein.
★ Said: Burkitt“Starry sky, you think Burkitt’s ... you’ll definitely see that on a test”; endemic = sub-Saharan Africa, “strongly, strongly, strongly associated with EBV” (slide 32).
★ Said: HodgkinReed-Sternberg cells = “automatically think of Hodgkin’s” (slide 36); ABVD = Hodgkin (slide 41); node pain after alcohol (slide 38).
★ Said: tumor lysis“A medical emergency ... you need to recognize it for your testing”: high potassium, phosphorus, uric acid (she added low calcium); fluids + allopurinol (slide 28).
★ Said: CLLHigh white count + painless nodes = think CLL; flow cytometry is the key test, CD19 + CD5 pathognomonic, so no marrow biopsy (slides 7–8); Richter transformation (slide 12); “an isolated white count alone does not equal treatment”.
★ Said: lymphomaInfections to know: HIV, EBV, HTLV-1, H. pylori (slide 23); excisional biopsy, never trust a negative fine needle aspiration; LDH on every lymphoma (slide 25); stage by the diaphragm (slide 26); T cells worse than B cells (slide 30).
Played downCD numbers beyond CD19/CD5; follicular t(14;18)/BCL-2; nodal and splenic marginal zone; mantle cell; Lyme and HHV-8; myeloma staging. Still on the slides.
★ Chronic lymphocytic leukemiaMature B cells (slide 4); frequently diagnosed while asymptomatic, painless lymphadenopathy, lymphocytosis >5K (slide 7); confirmed by flow cytometry, no marrow biopsy usually (slide 8); watch and wait (slide 11); Richter transformation (slide 12).
★ Non-Hodgkin85% B-cell, aggressive to indolent (slide 15); excisional biopsy and CT or PET (slide 25); tumor lysis syndrome: emergency, aggressive IV fluids (slide 28); poor-prognosis factors (slide 30).
★ Burkitt“Starry sky” (slide 32); prompt treatment, emergent referral; excellent prognosis if found early; tumor lysis (slide 33).
★ HodgkinReed-Sternberg cells (slide 36); bimodal, Epstein-Barr virus 40–50% (slide 37); painless cervical nodes (70%), pain with alcohol (slide 38); treatment by stage (slide 41); >90% alive at 5 years (slide 42).
★ MyelomaCRAB (slide 47); ≥10% plasma cells or plasmacytoma + 1 CRAB (slide 50); goal = prolonged remissions (slide 52); 3- or 4-drug regimen, most relapse (slide 53); shorter remissions each line, incurable (slide 54); smoldering 10% per year (slide 57).

Chronic Lymphocytic Leukemia

TermWhat you need to know
WhatProliferative leukemia of mature B-cell lymphocytes in blood, marrow, nodes, spleen (same disease as small lymphocytic lymphoma); 1% of United States cancers. Mature T-cell form: T-cell prolymphocytic leukemia.
Genes80%: del 13q, del 11q, trisomy 12, del 17p.
WhoMedian age 70; 2× males; Eastern European and Jewish descent; no known occupational or environmental risk factors.
PictureOften asymptomatic, routine labs; painless firm mobile nodes (50–90%); B symptoms 5–10%; fatigue, bruising, infections; splenomegaly ~40%.
DiagnosisFlow cytometry; ALC >5K x 3 months (or <5K with nodes/symptoms); CD19 + CD5; cytogenetics for prognosis; marrow biopsy usually not needed; Rai stage.
TreatWatch and wait until lymphocyte doubling <6 months or symptoms. BTK inhibitors (Bruton tyrosine kinase: ibrutinib, acalabrutinib, zanubrutinib; continuous); venetoclax (BCL-2) + antibody (fixed duration); rituximab, obinutuzumab, ofatumumab.
Outlook5-year relative survival ~88%; Richter transformation to aggressive B-cell lymphoma; many die with it, not from it; hematology/oncology, outpatient, pill (indefinite) or infusion + pill (time-limited).

Non-Hodgkin Lymphoma: Types

TermWhat you need to know
GroupLymphoid malignancy of B (85%), T or NK cells; 4% of United States cancers; very aggressive (Burkitt, diffuse large B-cell, T-cell leukemia/lymphoma) to indolent (follicular, marginal zone, chronic lymphocytic leukemia).
FollicularMost common indolent; waxing and waning painless nodes; t(14;18) BCL-2; packed follicles; often watch and wait; incurable.
Marginal zone5–17%; MALT most common (gut, eyes, lungs); gastric MALT 2/3 H. pylori; splenic = hepatitis C; older adults.
Lymphoplasmacytic= Waldenström macroglobulinemia; MYD88 ~90%; IgM → hyperviscosity (blurred vision, headache, rarely stroke); 5-year 78%; familial, farming, pesticides.
Diffuse large B-cellMost common non-Hodgkin lymphoma in adults; fast-growing mass and/or B symptoms; often curable (slide 34’s cure figure corrected out loud upward).
Mantle cellRare (5%); cyclin D1 t(11;14); aggressive; men 60–70; survival <2 to >9 years.
T-cellPeripheral T-cell, not otherwise specified = most common (1/3); adult T-cell leukemia/lymphoma: HTLV-1, Caribbean, Central and South America; NK/T-cell: nasal.
Mycosis fungoidesSkin lesions like a fungal infection → nodules that may ulcerate; Sézary syndrome = erythroderma with severe itch; treat the skin.

Non-Hodgkin Lymphoma: Work-up & Care

TermWhat you need to know
RiskWhite, developed countries, male; immunosuppression, transplant; lupus, Sjögren, celiac, Crohn’s; DDT (farming); H. pylori, HTLV-1, hepatitis C, HIV, Epstein-Barr virus, Lyme, HHV-8; family history.
PicturePeripheral nodes >2/3; B symptoms; pruritus, rash; extranodal in about half (CNS lymphoma: headache, neuro deficits); mediastinal B-cell: mass, cough, abnormal chest X-ray.
DiagnosisExcisional lymph node biopsy (2 cm, persistent, growing); not fine needle aspiration (architecture); CT or PET; CBC, chemistries (tumor lysis), LDH; marrow biopsy; lumbar puncture for high-grade incl. Burkitt.
Chemo harmsInfections, bleeding, anemia, electrolyte abnormalities, diarrhea (all agents).
TeachHematologist, ideally a lymphoma expert; outpatient unless aggressive with electrolyte problems; Burkitt: rapid transfer; fluids + allopurinol.

Burkitt Lymphoma

TermWhat you need to know
WhatVery aggressive; MYC upregulation; very rapidly growing, often painless swelling (visible change within a day); B symptoms.
Three typesEndemic: sub-Saharan Africa, New Guinea, Epstein-Barr virus. Sporadic: United States, Western Europe, males, almost always <35. Immunodeficiency: HIV/AIDS.
Pathology“Starry sky”: sheets of lymphoma with benign macrophages clearing dying cells.
ActPrompt treatment, emergent hematology referral; doubling within 24 hours; multi-agent chemotherapy; watch for tumor lysis; lumbar puncture in work-up.
OutlookExcellent if early: >90% children, 50–90% adults.

Hodgkin Lymphoma

TermWhat you need to know
WhatB-cell lymphoma: few Reed-Sternberg cells (binucleated, neoplastic B cells) among many immune cells; contiguous, orderly spread; 10–15% of lymphomas.
WhoBimodal: 20s and >60; same-sex sibling 10×; Epstein-Barr virus 40–50%; HIV, HHV-6, tuberculosis.
PicturePainless asymptomatic nodes (70%), usually cervical (supraclavicular, mediastinal); pain with alcohol; mediastinal mass on chest X-ray; splenomegaly ~30%; intense pruritus.
DiagnosisExcisional biopsy, not fine needle aspiration; CD15 and CD30; chest X-ray; CBC, chemistries, LDH; marrow biopsy; Lugano stage.
Outlook>90% alive at 5 years; relapse → allogeneic stem cell transplant; worse: older, bulky, lymphocyte-depleted or mixed cellularity; late myelodysplastic syndrome, secondary leukemia, other cancers.

Multiple Myeloma

TermWhat you need to know
WhatPlasma cell (terminally differentiated B cell) clone making one antibody, most commonly IgG; 10% of hematologic malignancies; spectrum MGUS → smoldering → myeloma.
MechanismOsteoclast activation → calcium release; kidney injury from light chain and calcium phosphate deposition; anemia from kidney and marrow.
WhoMost over 65; African Americans higher risk; family history; prior MGUS or smoldering myeloma; radiation, chemical, occupational.
PictureCRAB; infections; skull “punched out” lytic lesions.
DifferentialSmoldering myeloma, MGUS; Waldenström (IgM); chronic lymphocytic leukemia, non-Hodgkin lymphoma, amyloidosis; reactive hypergammaglobulinemia (cirrhosis, inflammation).
Work-upM-protein on serum protein electrophoresis; urine Bence Jones protein; CBC, metabolic panel; 24-hour urine protein electrophoresis; marrow biopsy with flow; kappa/lambda ratio; beta-2 microglobulin; whole-body CT.
TreatGoal: prolonged remissions, survival, quality of life. Proteasome inhibitor + immunomodulatory drug + steroid (3–4 drugs); autologous transplant + maintenance if a candidate; continuous therapy at relapse; CAR-T, bispecifics for relapse.
Outlook5-year relative survival ~60%; shorter remission each line; incurable; may exceed 10 years today; lifelong follow-up with a myeloma expert.